Literature DB >> 24621210

Pancreatic cancer: current standards, working towards a new therapeutic approach.

Olugbenga Olowokure1, Xiaoyang Qi.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer deaths with a 5-year survival of 4-6%. Clinical challenges remain to be addressed, since few promising approaches to treat pancreatic cancer have been reported. Here we discuss the potential of a new biotherapeutic agent composed of a lysosomal protein (Saposin C, SapC) and an acidic phospholipid (dioleoylphosphatidylserine, DOPS) which can be assembled into stable nanovesicles (SapC-DOPS) for tackling pancreatic cancer. Phosphatidylserine (PS) is a lipid biomarker on membrane surface of pancreatic cancer cells and can be effectively targeted by SapC-DOPS nanovesicles for cancer-selective therapy. SapC-DOPS nanovesicles have shown excellent pre-clinical therapeutic and safety profiles. Safety profiles which suggests that this new approach is potentially a viable option for pancreatic cancer therapy that is worthy of further clinical development.

Entities:  

Mesh：

Year:  2014        PMID： 24621210      PMCID： PMC4086873          DOI： 10.1586/14737140.2014.895937

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  21 in total

1.  Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.

Authors:  Steven R Alberts; Mark Schroeder; Charles Erlichman; Preston D Steen; Nathan R Foster; Dennis F Moore; Kendrith M Rowland; Suresh Nair; Loren K Tschetter; Tom R Fitch
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

2.  Functional organization of saposin C. Definition of the neurotrophic and acid beta-glucosidase activation regions.

Authors:  X Qi; W Qin; Y Sun; K Kondoh; G A Grabowski
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

Authors:  C J Bruns; C C Solorzano; M T Harbison; S Ozawa; R Tsan; D Fan; J Abbruzzese; P Traxler; E Buchdunger; R Radinsky; I J Fidler
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

5.  Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase.

Authors:  X Qi; T Leonova; G A Grabowski
Journal:  J Biol Chem       Date:  1994-06-17       Impact factor: 5.157

6.  Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.

Authors:  Jeffrey Wojton; Zhengtao Chu; Haritha Mathsyaraja; Walter H Meisen; Nicholas Denton; Chang-Hyuk Kwon; Lionel Ml Chow; Mary Palascak; Robert Franco; Tristan Bourdeau; Sherry Thornton; Michael C Ostrowski; Balveen Kaur; Xiaoyang Qi
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

7.  Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma.

Authors:  Dusten Unruh; Kevin Turner; Ramprasad Srinivasan; Begüm Kocatürk; Xiaoyang Qi; Zhengtao Chu; Bruce J Aronow; David R Plas; Catherine A Gallo; Holger Kalthoff; Daniel Kirchhofer; Wolfram Ruf; Syed A Ahmad; Fred V Lucas; Henri H Versteeg; Vladimir Y Bogdanov
Journal:  Int J Cancer       Date:  2013-07-27       Impact factor: 7.396

8.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

9.  Fusogenic domain and lysines in saposin C.

Authors:  Xiaoyang Qi; Zhengtao Chu
Journal:  Arch Biochem Biophys       Date:  2004-04-15       Impact factor: 4.013

10.  Phospholipid vesicle fusion induced by saposin C.

Authors:  Ying Wang; Gregory A Grabowski; Xiaoyang Qi
Journal:  Arch Biochem Biophys       Date:  2003-07-01       Impact factor: 4.013
View more
  7 in total

Review 1.  "Eat me" imaging and therapy.

Authors:  Vaishali Bagalkot; Jeffrey A Deiuliis; Sanjay Rajagopalan; Andrei Maiseyeu
Journal:  Adv Drug Deliv Rev       Date:  2016-01-27       Impact factor: 15.470

2.  Characteristics of gastrointestinal hemorrhage associated with pancreatic cancer: A retrospective review of 246 cases.

Authors:  Y U Wang; Caijun Yuan; Xiaomei Liu
Journal:  Mol Clin Oncol       Date:  2015-05-11

Review 3.  Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy.

Authors:  Ahmet Kaynak; Harold W Davis; Andrei B Kogan; Jing-Huei Lee; Daria A Narmoneva; Xiaoyang Qi
Journal:  Cancers (Basel)       Date:  2022-05-21       Impact factor: 6.575

Review 4.  Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles.

Authors:  Victor M Blanco; Tahir Latif; Zhengtao Chu; Xiaoyang Qi
Journal:  Transl Oncol       Date:  2015-06       Impact factor: 4.243

5.  SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas.

Authors:  Mahaboob K Sulaiman; Zhengtao Chu; Victor M Blanco; Subrahmanya D Vallabhapurapu; Robert S Franco; Xiaoyang Qi
Journal:  Mol Cancer       Date:  2015-04-08       Impact factor: 27.401

6.  Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.

Authors:  Kun Fan; Zhiyao Fan; He Cheng; Qiuyi Huang; Chao Yang; Kaizhou Jin; Guopei Luo; Xianjun Yu; Chen Liu
Journal:  Cancer Med       Date:  2019-08-19       Impact factor: 4.452

Review 7.  SapC-DOPS - a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy.

Authors:  Kombo F N'Guessan; Priyankaben H Patel; Xiaoyang Qi
Journal:  Cell Commun Signal       Date:  2020-01-09       Impact factor: 5.712
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.